ARTICLE | Product Development
Barron’s departure leaves unfinished business in GSK’s cancer pipeline
CSO stepping down to join biopharma ‘dream team’ at newly launched Altos
January 20, 2022 2:13 AM UTC
With Hal Barron’s departure from GlaxoSmithKline, one of the biggest jobs for the incoming CSO will be fixing the oncology business Barron set out to recreate.
On Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced that Barron will be leaving his role as CSO in August to take another shot at extending human longevity as CEO of newly launched Altos Labs Inc. ...